Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valsartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valsartan SCHEMBL29518879 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL8476946 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL24722321 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL678796 | 1.00 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL31532957 | 0.99 | AGTR1 (0.98) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL28804181 | 0.94 | AGTR1 (0.90) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL24224463 | 0.93 | AGTR1 (0.87) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL20257282 | 0.93 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL16482977 | 0.93 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL1828137 | 0.93 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1016 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288263-B1 | CONTAINER FOR A TOILET RIM CAGE | BUCK IND GMBH (DE) | 2025-07-16 | — | — | EP | claimed |
| EP-3919245-B1 | GLUE-LAMINATED BAMBOO HAVING INFINITE RANDOM LENGTH, AND METHOD FOR MANUFACTURING SAME | HUNAN TAOHUAJIANG BAMBOO SCIENCE & TECH CO LTD (CN) | 2025-05-28 | — | — | EP | claimed |
| WO-2025040453-A1 | METHOD AND DEVICE FOR PRODUCING A METALLURGICAL JOINT | Strunk Connect automated solutions GmbH & Co. KG (DE) | 2025-02-27 | — | — | WO | claimed |
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| EP-4288263-A1 | CONTAINER FOR A TOILET RIM CAGE | Buck Industries GmbH (DE) | 2023-12-13 | — | — | EP | claimed |
| EP-3197285-B1 | SEQUENTIAL METHOD FOR PRODUCING PURIFIED, COLD-PRESSED LINSEED OIL WITH ENHANCED WOOD PENETRATION PROPERTIES | SAGA WOOD HOLDING AS (NO) | 2023-09-06 | — | — | EP | claimed |
| WO-2023147928-A1 | CONTAINER FOR A TOILET RIM CAGE | BUCK INDUSTRIES GMBH (DE) | 2023-08-10 | — | — | WO | claimed |
| US-20230129331-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-04-27 | — | — | US | claimed |
| EP-4125809-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2023-02-08 | — | — | EP | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| CN-103599084-A | Antihypertensive composition | DISHA PHARMACEUTICAL GROUP CO | 2014-02-26 | — | — | CN | claimed |
| WO-2014006020-A1 | GPBP-1 INHIBITION AND ITS THERAPEUTIC USE | FIBROSTATIN, S.L. (ES) | 2014-01-09 | — | — | WO | claimed |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | UNIVERSITAT DE VALENCIA (ES) | 2014-01-02 | — | — | US | claimed |
| US-20120302526-A1 | METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-11-29 | — | — | US | claimed |
| CN-102670485-A | Method for researching and controlling hydrolysis impurity H in solid composition containing valsartan | CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD | 2012-09-19 | — | — | CN | claimed |
| CN-102204907-A | Pharmaceutical composition containing valsartan, and preparation method thereof | BEIJING SECOND PHARMACEUTICAL CO LTD | 2011-10-05 | — | — | CN | claimed |
| CN-101987098-A | Valsartan amlodipine medicine composition | TIANJIN HANKANG PHARMACEUTICAL BIO TECH CO LTD | 2011-03-23 | — | — | CN | claimed |
| CN-101836981-A | Compound valsartan benzenesulfonic acid amlodipine medicament composition and new preparation method thereof | JIE YAN | 2010-09-22 | — | — | CN | claimed |
| CN-101167723-B | Valsartan dispersible tablet and preparation method thereof | YIZHI CHEN | 2010-09-15 | — | — | CN | claimed |
| WO-1997030036-A1 | ARYL DERIVATIVES | NOVARTIS AG (CH) | 1997-08-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302526-A1 | METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | FKBP4, CRH, FKBP5 | AGTR1 1394/4885LTB4R2 915/4885ABCB11 3994/4885 |
| US-20230129331-A1 | LIPOSOMAL FORMULATIONS COMPRISING AT1 RECEPTOR BLOCKERS AND USES THEREOF | AGTR1, AGTR2, ADRB1 | AGTR1 1/4885LTB4R2 87/4885ABCB11 265/4885 |
| US-20140005134-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | AGTR1 770/4885LTB4R2 2435/4885ABCB11 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.